TriangleNCT00732641 · OUTCOME
Number of Days With Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Days
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)
What was measured
PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse. PFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse.
Analysis population: Intent-to-treat population (those who received at least one dose of study drug)
Groups in this outcome
Peginterferon α-2b
Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
No Treatment
Participants were observed and received no treatment
| Group | Source count |
|---|---|
| Peginterferon α-2b | 122 |
| No Treatment | 121 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Peginterferon α-2b | 1166 | Not reported | 682 | 1519 | Not reported |
| No Treatment | 519 | Not reported | 403 | 634 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 682
- upper Limit
- 1519
- value
- 1166
- group Id
- OG001
- lower Limit
- 403
- upper Limit
- 634
- value
- 519
- denoms
- counts
- group Id
- OG000
- value
- 122
- group Id
- OG001
- value
- 121
- units
- Participants
- description
- PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse. PFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
- id
- OG000
- title
- Peginterferon α-2b
- description
- Participants were observed and received no treatment
- id
- OG001
- title
- No Treatment
- param Type
- MEDIAN
- population Description
- Intent-to-treat population (those who received at least one dose of study drug)
- reporting Status
- POSTED
- time Frame
- Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)
- title
- Number of Days With Progression Free Survival (PFS)
- type
- PRIMARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice